A co-worker in my lab pointed out that Myriad's stock is actually rising[1] after the decision.The best guess is that Myriad's competitive advantage is shifting to the enormous amounts of BRCA sequences they have obtained -- this would increase the cancer-vs-normal mutation prediction power considerably.

[1] - http://www.google.com/finance?cid=658315